10 assets in Mast Cell Leukemia

Therapeutic assets addressing Mast Cell Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fludarabine Mast Cell Leukemia	Fred Hutchinson Cancer Center	P2	BB (65)
Bezuclastinib Mast Cell Leukemia	Cogent Biosciences, Inc.	P2	CCC (53)
Busulfanum Mast Cell Leukemia	Fred Hutchinson Cancer Center	P2	CCC (53)
Cyclophosphamide Mast Cell Leukemia	Fred Hutchinson Cancer Center	P2	CCC (53)
Tacrolimus Mast Cell Leukemia	Fred Hutchinson Cancer Center	P2	CCC (53)
Thiotepa Mast Cell Leukemia	Fred Hutchinson Cancer Center	P2	CCC (53)
Methotrexate Mast Cell Leukemia	Fred Hutchinson Cancer Center	P2	CCC (52)